An Evaluation of Repeated Oral Doses of JNJ-64281802 Against DENV-3 Challenge
Completed · Phase 2 · Has a placebo group
Conditions studied: Dengue
In brief
The investigational study drug, JNJ-64281802, is being developed for the prevention and treatment of dengue infection. This study is hypothesizing that the highest dose of the investigational study drug is superior to receiving a placebo with respect to its antiviral activity in healthy adult participants inoculated with Dengue Serotype 3.
Key facts
- Study ID
- NCT05048875
- Run by
- National Institute of Allergy and Infectious Diseases (NIAID)
- People needed
- 56
- Starts
- 2022-02-03
- Expected to finish
- 2024-09-10
- Last updated by the study team
- 2025-04-24
Who can join
Age: 18 and older, up to 55. Sex: any. Healthy volunteers: accepted.
Where it is running
- Johns Hopkins University, Bloomberg School of Public Health — Baltimore, Maryland, United States
- University of Vermont Medical Center (UVMMC), Clinical Research Center — Burlington, Vermont, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.